Alzheimer's drug donanemab: what promising trial means for treatments

Results suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain over its potential side effects. Results suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain over its potential side effects.

Automated summary

The study indicates that the amyloid-targeting drug candidate has the potential to slow down cognitive decline in certain individuals, but concerns remain regarding its possible side effects.